1 / 20

KEYSTONE SYMPOSIA

KEYSTONE SYMPOSIA. Connecting the Scientific Community. Biomarker Discovery, Validation and Applications February 3-8, 2008 ∙ Granlibakken Conference Center and Lodge, Lake Tahoe, California. Organizers: Mark S. Boguski and Jean-Jacques Garaud Topics Include:

haroun
Download Presentation

KEYSTONE SYMPOSIA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. KEYSTONE SYMPOSIA Connecting the Scientific Community Biomarker Discovery, Validation and Applications February 3-8, 2008 ∙ Granlibakken Conference Center and Lodge, Lake Tahoe, California • Organizers: Mark S. Boguski and Jean-Jacques Garaud • Topics Include: • New Strategies for Biomarker Discovery and Use • Biomarker Qualification • Imaging Biomarkers • Genomic Strategies • Multiplex Biomarkers and System Response Profiles • New Technologies • Translational Medicine and the Critical Path To register or for more information on this and 50+ other conferences, please visit www.keystonesymposia.org/8B1 or call 800-253-0685. Keystone Symposia is a 501(c)3 nonprofit directed and supported by the scientific community. Conferences provide an opportunity for debate, exchange and learning combined with leisure activities in world-class settings.

  2. Preliminary analysis of TLAs* at the 2008 Keystone Biomarker Conference Dr. Mark Boguski www.markboguski.net February 8, 2008 *Three-Letter Acronyms

  3. TLAs used in oral presentations or abstracts BUN CAD CEA CIR CRC CSF DNA ESI FDA FDG FDR FHF GBM GSH HDG HIV HPV HTG IFX LDA LPS MDA MEF MRI MRM MRS NAC NIH OOB PCR PET PLA PSA RCC RNA SDA SIV SSC TIA TMA

  4. Supervised clustering shows 6 categories BUN CAD CEA CIR CRC CSF DNA ESI FDA FDG FDR FHF GBM GSH HDG HIV HPV HTG IFX LDA LPS MDA MEF MRI MRM MRS NAC NIH OOB PCR PET PLA PSA RCC RNA SDA SIV SSC TIA TMA

  5. Work is being done on a variety of diseases BUN CAD CEA CIR CRC CSF DNA ESI FDA FDG FDR FHF GBM GSH HDG HIV HPV HTG IFX LDA LPS MDA MEF MRI MRM MRS NAC NIH OOB PCR PET PLA PSA RCC RNA SDA SIV SSC TIA TMA

  6. The number of validated biomarkers is small BUN CAD CEA CIR CRC CSF DNA ESI FDA FDG FDR FHF GBM GSH HDG HIV HPV HTG IFX LDA LPS MDA MEF MRI MRM MRS NAC NIH OOB PCR PET PLA PSA RCC RNA SDA SIV SSC TIA TMA

  7. A variety of research methods are being used BUN CAD CEA CIR CRC CSF DNA ESI FDA FDG FDR FHF GBM GSH HDG HIV HPV HTG IFX LDA LPS MDA MEF MRI MRM MRS NAC NIH OOB PCR PET PLA PSA RCC RNA SDA SIV SSC TIA TMA Experimental Methods

  8. A variety of research methods are being used BUN CAD CEA CIR CRC CSF DNA ESI FDA FDG FDR FHF GBM GSH HDG HIV HPV HTG IFX LDA LPS MDA MEF MRI MRM MRS NAC NIH OOB PCR PET PLA PSA RCC RNA SDA SIV SSC TIA TMA Imaging Methods

  9. A variety of research methods are being used BUN CAD CEA CIR CRC CSF DNA ESI FDA FDG FDR FHF GBM GSH HDG HIV HPV HTG IFX LDA LPS MDA MEF MRM MRS NAC NIH OOB PCR PET PLA PSA RCC RNA SDA SIV SSC TIA TMA Mathematical Methods

  10. A variety of research methods are being used BUN CAD CEA CIR CRC CSF DNA ESI FDA FDG FDR FHF GBM GSH HDG HIV HPV HTG IFX LDA LPS MDA MEF MRI MRM MRS NAC NIH OOB PCR PET PLA PSA RCC RNA SDA SIV SSC TIA TMA All Methods

  11. A variety of compounds and reagents are being used BUN CAD CEA CIR CRC CSF DNA ESI FDA FDG FDR FHF GBM GSH HDG HIV HPV HTG IFX LDA LPS MDA MEF MRI MRM MRS NAC NIH OOB PCR PET PLA PSA RCC RNA SDA SIV SSC TIA TMA

  12. Only two organizations are interested in or are supporting the work BUN CAD CEA CIR CRC CSF DNA ESI FDA FDG FDR FHF GBM GSH HDG HIV HPV HTG IFX LDA LPS MDA MEF MRI MRM MRS NAC NIH OOB PCR PET PLA PSA RCC RNA SDA SIV SSC TIA TMA

  13. Some data remains unclassified BUN CAD CEA CIR CRC CSF DNA ESI FDA FDG FDR FHF GBM GSH HDG HIV HPV HTG IFX LDA LPS MDA MEF MRI MRM MRS NAC NIH OOB PCR PET PLA PSA RCC RNA SDA SIV SSC TIA TMA

  14. Some data remains unclassified BUN CAD CEA CIR CRC CSF DNA ESI FDA FDG FDR FHF GBM GSH HDG HIV HPV HTG IFX LDA LPS MDA MEF MRI MRM MRS NAC NIH OOB PCR PET PLA PSA RCC RNA “Out-Of-Bag” !? SDA SIV SSC TIA TMA

  15. Summary and Conclusions BUN CAD CEA CIR CRC CSF DNA ESI FDA FDG FDR FHF GBM GSH HDG HIV HPV HTG IFX LDA LPS MDA MEF MRI MRM MRS NAC NIH OOB PCR PET PLA PSA RCC RNA SDA SIV SSC TIA TMA

  16. Summary and Conclusions BUN CAD CEA CIR CRC CSF DNA ESI FDA FDG FDR FHF GBM GSH HDG HIV HPV HTG IFX LDA LPS MDA MEF MRI MRM MRS NAC NIH OOB PCR PET PLA PSA RCC RNA SDA SIV SSC TIA TMA

  17. Summary and Conclusions BUN CAD CEA CIR CRC CSF DNA ESI FDA FDG FDR FHF GBM GSH HDG HIV HPV HTG IFX LDA LPS MDA MEF MRI MRM MRS NAC NIH OOB PCR PET PLA PSA RCC RNA SDA SIV SSC TIA TMA

  18. Summary and Conclusions BUN CAD CEA CIR CRC CSF DNA ESI FDA FDG FDR FHF GBM GSH HDG HIV HPV HTG IFX LDA LPS MDA MEF MRI MRM MRS NAC NIH OOB PCR PET PLA PSA RCC RNA SDA SIV SSC TIA TMA

  19. That’s all folks. Supplemental Slides Follow

  20. TLAs used in oral presentations or abstracts

More Related